anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The study will evaluate the use and preliminary impact of an mHealth app for improving sexual health outcome measures among male couples by assessing whether exposure and use of the app results in improvements in participants and couples' self-reported sexual health and prevention behaviors, beliefs, and attitudes. The study will enroll both partners of the 42 male couples into a 2-month randomized controlled trial with a waitlist control condition of one month. Couples will be assigned to either the immediate intervention group ("intervention arm") or the waitlist-control group ("waitlist-control arm"). All participants will take an assessment survey at baseline, and the intervention group will be oriented on the installation and use of the app upon randomization to that group. The waitlist-control group will follow the same procedures one month later. Participants/couples randomized to the intervention arm will have access to the intervention app for two months (ie, day 1-60) while those assigned to the waitlist-control group will have access to the app for one month (ie, day 31-60). All participants in the randomized controlled trial will complete a short follow-up survey at month 2 and a brief exit interview.
FIELD: biochemistry, labeled compounds. SUBSTANCE: invention relates to method for radioactive labeling proteins with therapeutic radioactive isotope for administration to patient. Method involves mixing protein or peptide conjugated with chelating agent with solution containing radioactive isotope or its salts, acceptable buffer, incubation for sufficient time at acceptable pH value and temperature that provides preparing the end product with radiochemical purity above 95%, sufficient specific activity and specificity binding at least about 50%. Prepared product can be administrated to patient without additional purification. Invention relates also to a set for realization of method representing flask containing protein or peptide conjugated with chelating agent in acceptable buffer, flask containing the composition buffer for stabilization and administration of radiolabeled protein or peptide to patient and instruction for carrying out procedure of radioactive labeling. EFFECT: improved labeling method. 50 cl, 8 tbl, 2 dwg, 3 ex
One aspect of the present invention relates to pharmaceutical compositions comprising optically pure (S)-amlodipine and a cholesteryl ester transfer protein inhibitor. In certain embodiments, the cholesteryl ester transfer protein is torcetrapib, JTT-705, or SC-795. In a preferred embodiment, the cholesteryl ester transfer protein is torcetrapib. In certain embodiments, said optically pure (S)-amlodipine is optically pure (S)-amlodipine malate, or a polymorph, pseudopolymorph or solvate thereof. Another aspect of the present invention relates to a method of treating a patient suffering from hypertension, hyperlipidemia, or a cardiac disorder, comprising co-administering a therapeutically effective amount of optically pure (S)-amlodipine and a cholesteryl ester transfer protein inhibitor. In certain embodiments, said optically pure (S)-amlodipine is optically pure (S)­amlodipine malate, or a polymorph, pseudopolymorph or solvate thereof.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to ophthalmology, and can be used for surgical treatment of idiopathic macular retinal ruptures. Method for obtaining an autologous thrombocyte-enriched blood plasma involves sampling venous blood in a syringe connected to the catheter and having a preset anticoagulant. Syringe is closed, the contents are mixed and introduced into the YCELLBIO-KIT test tube by 18 G needle through the paracentral opening in the test tube lid. Centrifugation is performed at room temperature with rotation speed 4,000 rpm for 5 minutes. Plasma layer rich in thrombocytes is extracted with blunt-ended 27 G thin-walled cannula through a central opening in a test tube lid. Venous blood volume for males is 12.5 ml, while for females – 13.5.EFFECT: invention enables producing an autologous thrombocyte-rich plasma with a high thrombocyte content from a small amount of blood.1 cl, 2 ex
PURPOSE:To obtain a medicine having excellent properties as pharmaceutical preparation little forming a decomposition product with light rays during preservation, capable of storing a nicergolin preparation for a long period of time. CONSTITUTION:Nicergolin is blended with lactose and white sugar to give a preparation for oral administration. For example, a preparation wherein 1 pt.wt. nicergolin is blended with 2-950 pts.wt. lactose, most preferably about 10-200 pts.wt. lactose and about 0.5-200 pts.wt., most preferably about 3-30 pts.wt. white sugar in preparation may be cited as the preparation.
The present invention is directed to certain aza cyclophexapeptide compounds having given general structure formula. These compounds are characterised in having a nitrogen attached to the cyclohexapeptide ring at the 5-carbon of the 4-hydroxy ornithine component. The compounds of the present invention are generally obtained as mixtures of stereoisomeric forms in which one form usually predominates. The compounds described, their pharmaceutically acceptable salts and acid addition salts are useful as an antibiotic, especially as an antifungal agent or as an antiprotozoal agent. As antifungal agents they are useful for the control of both filamentous fungi and yeasts. They are especially adaptable to be employed for the treatment of mycotic infections caused by Candida species, Cryptococcus species and Aspergillus species. They are also useful for the treatment and/or prevention of Pneumocystis carnii pneumonia to which immune-compromised patients are especially susceptible.
1411547 Antiperspirants UNILEVER Ltd 26 Jan 1973 [28 Jan 1972] 4182/72 Heading A5B Aerosol antiperspirant compositions substantially free from the development of off-odours comprise a dispersion of an acidic antiperspirant agent in a medium comprising hexylene glycol and a base and a propellant. The base is preferably a weak base such as 2-amino-2- methylpropan-1-ol, 2-amino-2-methyl-propan-1, 3-diol or monoethanolamine but strong bases such as the alkali-metal hydroxides, triethanolamine and ammonia may also be used. The antiperspirant agent may be aluminium chlorhydrate or zinc phenolsulphonate. The composition may also contain a bulking agent e.g. a silica, a germicide e.g. chlorhexidine, dichlorophene, or cetyltrimethylammonium bromide, a nonionic surfactant and/or a perfume.
Systemic sclerosis (SSc) is an autoimmune systemic disease that is characterized by immune dysregulation, inflammation, vasculopathy, and fibrosis. Tissue fibrosis plays an important role in SSc and can affect several organs such as the dermis, lungs, and heart. Dysregulation of interferon (IFN) signaling contributes to the SSc pathogenesis and interferon regulatory factor 1 (IRF1) has been indicated as the main regulator of type I IFN. This study aimed to clarify the effect of IFN-gamma (-γ) and dexamethasone (DEX) on the IRF1, extracellular signal-regulated kinase 1/2 (ERK1/2), and the expression of alpha-smooth muscle actin (α-SMA) in myofibroblasts and genes involved in the inflammation and fibrosis processes in early diffuse cutaneous systemic sclerosis (dcSSc). A total of 10 early dcSSc patients (diffuse cutaneous form) and 10 unaffected control dermis biopsies were obtained to determine IFNγ and DEX effects on inflammation and fibrosis. Fibroblasts were treated with IFNγ and DEX at optimum time and dose. The expression level of genes and proteins involved in the fibrosis and inflammation processes have been quantified by quantitative real-time PCR (RT-qPCR) and western blot, respectively. IFNγ could up-regulate some of the inflammation-related genes (Interleukin-6; IL6) and down-regulate some of the fibrosis-related genes (COL1A1) in cultured fibroblasts of patients with early dcSSc compared to the untreated group. Besides, it has been revealed that IFNγ can induce fibroblast differentiation to the myofibroblast that expresses α-SMA. Concerning the inhibitory effect of IFNγ on some fibrotic genes and its positive effect on the inflammatory genes and myofibroblast differentiation, it seems that IFNγ may play a dual role in SSc.
Etoposide Injection USP must be diluted prior to use with either 5% Dextrose Injection, or 0.9% Sodium Chloride Injection, to give a final concentration of 0.2 to 0.4 mg/mL. If solutions are prepared at concentrations above 0.4 mg/mL, precipitation may occur. Hypotension following rapid intravenous administration has been reported; hence, it is recommended that the etoposide Injection USP solution be administered over a 30- to 60-minute period. A longer duration of administration may be used if the volume of fluid to be infused is a concern. 

Etoposide Injection USP should not be given by rapid intravenous injection.

Parenteral drug products should be inspected visually for particulate matter and discoloration (See DESCRIPTION) prior to administration whenever solution and container permit.
Initial Screening and Study enrollment will begin in 2021 among adults residing in the Greater Seattle area. Participants will be recruited and driven to the online Study Website managed by UW. If determined to be eligible following completion of the Prescreen Consent and an initial eligibility assessment via REDCap, potential participants will be asked to review and, if interested in participation, to complete the Main Study Consent via REDCap, as well as to engage in enrollment procedures across both REDCap and the Apple Research app. Redcap will be used for prescreening, enrollment survey, and kit activation survey. Participants will use the Apple Research app to complete onboarding surveys, weekly symptom surveys, illness follow-up surveys, and monthly lifestyle surveys. These surveys will help the investigators learn about onset of respiratory symptoms as well as sick contacts, flu and/or COVID-19 vaccination and risk factors for illness. Participants will also receive an Apple Watch to capture certain sensor data-which, along with iPhone sensor data, will be correlated with symptom onset and symptom trajectory. If a participant experiences an acute respiratory illness (ARI), defined as at least one respiratory symptom for at least 24 hours, that individual will be asked to complete a symptom onset survey and self-collect an anterior nasal swab, which will be sent to UW Laboratory Medicine for analysis. Participants will be able to access their COVID swab test results using a secure web portal. Additionally, individuals who test positive or inconclusive for SARS-CoV-2 will be notified via phone by the UW Study Team and given instructions as defined by and in accordance with state, local, and national public health guidance.
Since 2013, therapeutic care of metastatic melanoma (MM) has greatly improved, especially thanks to BRAF and MEK targeted therapies. The efficacy of these treatments that are now used daily at first line for BRAF mutated MM is widely approved. Their toxicities, in monotherapy or in association, are also well-known: fever, arthralgias, digestive disorders, cutaneous rash, fatigue, photosensitivity, alopecia, cutaneous hyperkeratosis, squamous cell carcinomas, keratoacanthomas, de novo melanomas... However, onco-dermatologists are more and more faced with MM of elderly patients. Indeed, life expectancy continues to increase and the over-75-year-old age group is becoming larger. These patients are still active but much more vulnerable. Nevertheless, there is no data in the literature for this fragile population except the MM pivotal studies subgroups of those over 65-year-old. The results vary with different regimens. Therefore, there is a wide lack of information that could help make a therapeutic decision, inform patients, prevent or treat side effects of BRAF and MEK inhibitors in elderly patients. This work aims to study the targeted therapies tolerance in over 65 or 75-year-old patients with BRAF mutated MM. The French clinical and biological database MELBASE will be analysed to carry out a descriptive retrospective multicentric study. This real-life assessment of the adverse effects in older patients will result in more adapted therapeutic decisions, better informed patients and improved follow-up care in order to increase quality of life and life expectancy.
NEW MATERIAL:A compound expressed by formula I (R1 to R3 are lower alkyl or phenyl; R4 is H, lower acyl or formula II). EXAMPLE:N<2>-tert-Butyldimethylsilyl-9-(tert-butyldimethylsilyloxyetho xymethyl) guanine. USE:An antiviral agent. PREPARATION:9-(2-Hydroxyethoxymethyl)guanine expressed by formula III is reacted with a halogenosilyl compound expressed by formula IV (X is halogen) in the presence of a basic catalyst in a suitable solvent (e.g. aromatic hydrooarbons or ethers) to afford the compound expressed by formula I (R4 is R or formula II). An acid anhydride is reacted with the resultant compound expressed by formula I (R4 is H) to provide the compound expressed by formula I (R4 is lower acyl).
* Bone marrow depression [see Warnings and Precautions (5.2)].   

  * Known hypersensitivity to carbamazepine, such as anaphylaxis or serious hypersensitivity reaction [see Warnings and Precautions (5.3)].   

  * Known hypersensitivity to any of the tricyclic compounds (e.g., amitriptyline, desipramine, imipramine, protriptyline, and nortriptyline.) Hypersensitivity reactions include anaphylaxis and serious rash.  

  * Concomitant use of delavirdine or other non-nucleoside reverse transcriptase inhibitors that are substrates for CYP3A4. EQUETRO can substantially reduce the concentrations of these drugs through induction of CYP3A4. This can lead to loss of virologic response and possible resistance to these medications [see Warnings and Precautions (5.9) and Drug Interactions (7.2)].   

  * Concomitant use of monoamine oxidase inhibitors (MAOIs). Before beginning treatment with EQUETRO, MAOIs should be discontinued for a minimum of 14 days. Concomitant use can cause serotonin syndrome.  

  * Concomitant use of nefazodone. This may result in insufficient plasma concentrations of nefazodone and its active metabolite to achieve a therapeutic effect.
PURPOSE: A papiliocin 2 gene isolated from a Papilio xuthus larva, an antipeptide using the same, and a method for producing a large amount of recombinant papiliocin 2 are provided to ensure antibacterial activity against gram-negative bacteria, Candida albicans, and resistant bacteria(MEREC). CONSTITUTION: A gene of antibacterial peptide papiliocin 2 is denoted by sequence number 7 and is isolated from Papilio xuthus larva. A recombinant antibacterial peptide papiliocin 2 is denoted by sequence number 9. A recombinant expression vector, pET32-Papiliocin2 contains the recombinant antibacterial peptide papiliocin 2. A recombinant E.col BL21(DE3)-(pET32-Papiliocin2) is formed by transforming with the recombinant expression vector pET32-Papiliocin2. A method for producing a large amount of the recombinant antibacterial peptide pailiocin 2 comprises: a step of preparing the recombinant antibacterial peptide papiliocin 2(sequence number 9); a step of preparing the recombinant E.coli by the recombinant expression vector containing the recombinant antibacterial peptide papiliocin 2; and a step of culturing the recombinant E.coli and isolating and purifying a water soluble recombinant fusion protein.
Relapsing-remitting (RR) Multiple Sclerosis (MS) is the most common form of the disease; RRMS patients can maintain their clinical phenotype throughout life or can develop a secondary progressive (SP) course over time. We investigated whether circulating miRNAs can predict RR-to-SPMS conversion. A serum miRNAs profile was initially analyzed in a cross-sectional study by qPCR in 16 patients (8 RRMS and 8 SPMS) (Discovery cohort). Three miRNAs, i.e. miR-34a-5p, miR-103a-3p and miR-376a-3p, were significantly up-regulated in SPMS compared to RRMS patients (p < 0.0 5). Serum concentration of the same miRNAs was subsequently analyzed in a retrospective study by ddPCR at baseline in 69 RRMS patients who did (N = 36 cSPMS) or did not (N = 33) convert into SPMS over a 10-year observation period (Study cohort). The results showed that these miRNAs were significantly increased at baseline only in those RRMS patients who converted to SPMS over time. miR-34a-5p and miR-376a-3p alone were significantly increased in cSPMS sera at the end of the 10-years period too. Serum concentration of miR-34a-5p, miR-103a-3p and miR-376a-3p is increased in RRMS patients several years before their conversion to SPMS. These miRNAs might be useful biomarkers to predict the conversion from RRMS to SPMS.
Participants will receive i.v. bimagrumab 30 mg/kg at baseline, and at Weeks 4, 16, 28, 40, 52 and 64, and s.c. semaglutide 1.0 mg weekly per the dose escalation schedule.
Pregnancy Category C. Reproduction studies have been performed in rabbits and rats at oral doses up to 1.5 (15 mg/kg/day) and 6 (60 mg/kg/day) times the human oral daily dose, respectively, and have revealed no evidence of teratogenicity. In the rat, however, this multiple of the human dose was embryocidal and retarded fetal growth and development, probably because of adverse maternal effects reflected in the reduced weight gains of the dams. This oral dose has also been shown to cause hypotension in rats. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Verapamil crosses the placental barrier and can be detected in umbilical vein blood at delivery.
This study aimed to investigate the reporting rates of arthritis and arthralgia following the administration of four vaccines against SARS-CoV-2: Pfizer-BioNTech (Tozinameran), Moderna (CX-024414), AstraZeneca (Chadox1 NCOV-19), and Janssen (AD26.COV2.S) in 2021. We used data from the EudraVigilance database, specifically analyzing spontaneous reports of suspected adverse reactions (ADRs) from the European Union (EU)/European Economic Area (EEA) region. Age-group-specific reporting rates were calculated by dividing the number of arthralgia and arthritis reports per 1,000,000 vaccine doses administered per age group. Reporting rates were compared using a rate ratio among the four vaccines, using the AstraZeneca vaccine as a comparator. The AstraZeneca vaccine was associated with the highest rate of arthralgia across all age groups. Arthritis reporting rates were significantly lower, with the AstraZeneca vaccine having the highest rates in most age groups, except the 60-69 and 80+ groups, where the Janssen and Pfizer-BioNTech vaccines demonstrated higher reporting rates, respectively. The distribution of arthritis rates did not follow the arthralgia pattern, being higher in the 50-79 age group. This study is the first spontaneous reporting system analysis of arthritis reporting rates post-SARS-CoV-2 vaccination at a European level, revealing a higher reporting of suspected musculoskeletal adverse reactions after AstraZeneca vaccination. The findings underscore the need to consider commonly reported events like arthralgia in risk-benefit assessments prior to vaccination against SARS-CoV-2. Given the high prevalence of rheumatic and musculoskeletal diseases and vaccine hesitancy in this population, our results could influence vaccine choice and acceptance.
The invention discloses a slow-released preparation in treatment and prevention for rabbit malignant rhinitis and means of making thereof, belonging to the technical field for treating and prevention of livestock epidemic disease. Said preparation consists of Azithromycin and beta cyclodextrin as materials and prepares in accordance with part by weight; preparation means is, first mixing and dissolving Azithromycin and anhydrous alcohol in accordance with weight-to-volume ratio : 1g.: 7-9 ml.; mixing and grinding into paste beta cyclodextrin and distilled water in accordance with weight-to-volume ratio : 1g.: 0.5-1.5ml.; thereafter mixing, compounding, drying, grinding both described hereinabove to obtain slow-released powder; being prepared into injection when applying.
BACKGROUND  : Nephropathy in Denys-Drash syndrome (DDS) develops within a few months of birth, often progressing to kidney failure. Wilms tumors also develop at an early age with a high rate of incidence. When a patient does not have Wilms tumor but develops kidney failure, prophylactic bilateral nephrectomy, and kidney transplantation (KTX) is an optimal approach owing to the high risk of Wilms tumor development. In the case presented here, prophylactic bilateral nephrectomy and KTX were performed in a patient who had not developed Wilms tumor or kidney failure. However, the treatment option is controversial as it involves the removal of a tumor-free kidney and performing KTX in the absence of kidney failure. CASE DIAGNOSIS/TREATMENT: We present the case of a 7-year-old boy, born at 38 weeks gestation. Examinations at the age of 1 year revealed severe proteinuria and abnormal internal and external genitalia. Genetic testing identified a missense mutation in exon 9 of the WT1 gene, leading to the diagnosis of DDS. At the age of 6 years, he had not yet developed Wilms tumor and had grown to a size that allowed him to safely undergo a KTX. His kidney function was slowly deteriorating (chronic kidney disease (CKD) stage 3), but he had not yet developed kidney failure. Two treatment options were considered for this patient: observation until the development of kidney failure or prophylactic bilateral nephrectomy with KTX to avoid Wilms tumor development. After a detailed explanation of options to the patient and family, they decided to proceed with prophylactic bilateral nephrectomy and KTX. At the latest follow-up 4 months after KTX, the patient's kidney functioned well without proteinuria. CONCLUSION: We performed prophylactic bilateral nephrectomy with KTX on a DDS patient who had not developed kidney failure or Wilms tumor by the age of 7 years. Although the risk of development of Wilms tumor in such a patient is unclear, this treatment may be an optimal approach for patients who are physically able to undergo KTX, considering the potentially lethal nature of Wilms tumor in CKD patients.
In controlled clinical trials of up to 12 weeks' duration in patients with chronic stable angina, nicardipine hydrochloride capsules increased exercise tolerance and reduced nitroglycerin consumption and the frequency of anginal attacks. The antianginal efficacy of nicardipine hydrochloride capsules (20 to 40 mg) has been demonstrated in four placebo-controlled studies involving 258 patients with chronic stable angina. In exercise tolerance testing, nicardipine hydrochloride capsules significantly increased time to angina, total exercise duration and time to 1 mm ST segment depression. Included among these four studies was a dose-definition study in which dose-related improvements in exercise tolerance at 1 and 4 hours postdosing and reduced frequency of anginal attacks were seen at doses of 10, 20, and 30 mg tid. Effectiveness at 10 mg tid was, however, marginal. In a fifth placebo-controlled study, the antianginal efficacy of nicardipine hydrochloride capsules were demonstrated at 8 hours postdose (trough). The sustained efficacy of nicardipine hydrochloride capsules have been demonstrated over long-term dosing. Blood pressure fell in patients with angina by about 10/8 mm Hg at peak blood levels and was little different from placebo at trough blood levels.
Patients receive daratumumab IV on days 1, 8, 15, and 22 of courses 1-2, days 1 and 15 of courses 3-6, and day 1 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Beginning course 2, patients also receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.